【出展情報】
3rd Annual mRNA-Based Therapeutics Summitに出展致します。
ご参加の際はぜひ当社ポスターブースへお立ち寄りください。

【Summitの概要】https://mrnabased-therapeutics.com/

---

【開催日時】2023年7月26日～28日

【発表タイトル】
mRNA medicine development strategy as Japan’s first CRDMO Strategy for optimization of mRNA design

〇Akiko Yanagiya, Rena Akahori, Naoki Matsumoto, Daichi Matsuura, Tetsuo Yoshida, Jun Nihira, Kazuyuki Nakashima

【発表概要】
ARCALIS is the first GMP compliant CRDMO for mRNA-based therapeutics in Japan, which was established in April 2021 in Kashiwanoha, Chiba, Japan.
ARCALIS is a joint-venture of Axcelead (an integrated drug discovery platformer curved-out from Takeda pharmaceutical research division) and Arcturus (a unique manufacturing and process technology company for mRNA drug substance and LNP formulation.)
ARCALIS can provide mRNA-based therapeutics from CMC development to GMP-manufacturing seamlessly.
Here, we present our capabilities for developing mRNA medicines in terms of mRNA design, quality controls such as capping efficiency, the length of poly(A) tail and a potency assay for protein production.